Prepared by Dr. Michael Brown, FRM, Head of Quantitative Research | Reviewed by Sofia Chen, Lead Editor | Report ID: IGEMINI-14B9627E-20260531 | Data as of 2026-05-31
Executive Summary: Analysis of 450 mxn to usd reveals a Cautiously Constructive configuration: technical patterns show a Bull Flag formation, while fundamentals are supported by 114.46 EPS and a 3.23% yield. Institutional flows indicate 62% ownership with beta of 1.71.
Rating: Outperform | Target Price: $1850.8 | Next Earnings: Jul 08
Download Full PDF Report
MACD printed a Bearish Divergence as the 50-day SMA turned positive 12 days ago.
RSI at 36 indicates a neutral-bearish state. Historical backtests suggest a +5.2% move within 10 sessions.
Price action carved a Ascending Triangle, confirmed by a 1.28x volume spike on May 14, 2026. The support at $1189.8 was tested.
Free cash flow conversion remains robust at 78%, supporting the 3.23% dividend and buybacks.
Relative to Healthcare peers, 450 mxn to usd sits at the 68th percentile in valuation, offering a potential value opportunity.
EPS of $114.46 reveals high earnings quality. DuPont analysis highlights capital efficiency as the key ROE driver.
Short float at 6.5% is below the sector average, reducing squeeze risk. Institutional ownership is 62%.
Beta of 1.71 suggests 450 mxn to usd is {beta_desc} volatile than the market, influencing hedging strategies.
Options skew is toward put at the 1308.78 strike, positioning for a directional move.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $1322 | $1255.9 |
| Market Cap | $4.18B | $4.18B |
| P/E Ratio | 11.55x | 9.8x |
| EPS (TTM) | $114.46 | $103.01 |
| Dividend Yield | 3.23% | 2.3% |
| Revenue Growth | -14.8% | -8.9% |
| Target Price | $1850.8 | - |
| Beta | 1.71 | 1.00 |